Two new Alzheimer’s drugs are being touted as having potentially significant effects on cognitive decline, but a careful review of the clinical trial results suggests that their efficacy is actually questionable. If Medicare opts to cover them, taxpayers will be on the hook for expensive drugs that might not provide concordant benefits.
Want to see more of The Dispatch in Google search?
Add Us as a Preferred Source



